Promoter holding
64.27%
CS
Cordlife Sciences India Pvt Ltd - Due diligence report
A 360° intelligence report on Cordlife India: trust score, financial health, credit view, compliance, directors, growth and distress signals…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Cordlife India — 360° Intelligence Report
Generated from MCA filings & public records52/100
Trust Score
Moderate
Cordlife India is assessed as Moderate with a Trust Score of 52/100. Cordlife India is an active private limited indian non-government company incorporated in 2005, operating in the Healthcare sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.
Report generated on 23 Aug 2026 from the latest processed filings. Cordlife Sciences India Pvt Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
52/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
81/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
15/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
30/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
30/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 50/100 Moderate
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
Charges position: 0 open (-) · 1 satisfied (3.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Citi Bank N.A. | 1 | 48.0 cr |
Compliance Score: 81/100 Low Risk
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 30/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PROSANTO KUMAR CHOWDHURY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AMIT PRAKASH SRIVASTAVA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| THET HNIN YI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Vishal Kanodia | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAHUL GOYAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Amit Prakash Srivastava | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Arnabi Ghosh | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rahul Goyal | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- THET HNIN YI has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 5 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Cs Cell Technologies Pvt Ltd
Subsidiaries
-
Group entities
-
Capital events
17 allotment(s) · 1 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Cs Cell Technologies Pvt Ltd | Holding Company | 74.00% |
Key managerial personnel: AMIT PRAKASH SRIVASTAVA (CEO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 30
Growth signals & trust indicators
Operating for 20+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
5 director exits within 2 years.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence57/100
Review suggested
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 4 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment47/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
Investor view34/100
Limited indicators at present
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events24 Sep 2025
Director ceased
Amit Prakash Srivastava
Director ceased
Arnabi Ghosh
23 May 2025
Director appointed
Arnabi Ghosh (Director)
31 Mar 2025
Director appointed
Rahul Goyal (Company Secretary)
03 Mar 2025
Director appointed
RAHUL GOYAL (Company Secretary)
24 Dec 2024
Director appointed
THET HNIN YI (Additional Director)
Director appointed
Amit Prakash Srivastava (Director)
13 Sep 2024
Director appointed
Vishal Kanodia (Director)
Director ceased
Woon Geok Peng
Director ceased
Mitchelle Ho
Director ceased
Vishal Kanodia
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
20 Oct 2022
Director ceased
CHOO BOON YONG
01 Oct 2022
Director appointed
AMIT PRAKASH SRIVASTAVA (CEO)
10
Key Observations
Auto-generated from the data aboveRevenue declined 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Compliance record is strong - status, filings and flags are clean.
8 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 17 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Novaivffertility | U93000MH2014PTC416797 | Bandra, Maharashtra, India |
| Smart Vision Eye Specialities | U85100TG2016PTC111604 | Hyderabad, Telangana, India |
| Alto Medical Systems Private Limited | U51507TN2004PTC053494 | Chennai, Tamil Nadu, India |
| Namma Vaidyashaala | U85300KA2019PTC126011 | Malleshwaram, Karnataka, India |
| Medcis | U85110TG2010PTC070969 | Secunderabad, Telangana, India |
| Medicover Fertility | U74999TS2015FTC202164 | Shaikpet, Telangana, India |
| Accuprobe Healthcare And Diagnostics Private Limited | U74999DL2015PTC277429 | Delhi, Delhi, India |
| Atulaya Healthcare Private Limited | U85100CH2011PTC033238 | Chandigarh, Chandigarh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Cordlife India before audits and certifications: compliance score 81/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Cordlife India: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Cordlife India - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 52/100, distress signals and MSME payment-delay disclosures - know whether Cordlife India pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Cordlife India - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Cordlife India an active company?
Cordlife India has MCA status “Active” with a compliance score of 81/100 (Low Risk).
Is Cordlife India financially healthy?
Cordlife India has a Financial Health Score of 15/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Cordlife India?
Its overall Trust Score is 52/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Cordlife India?
The ultimate holding entity is Cs Cell Technologies Pvt Ltd. 8 active director(s) are on record.
Does Cordlife India have loans or charges against its assets?
No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Cordlife India up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 81/100 (Low Risk).
Is it risky to lend to Cordlife India?
Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
